GP laboratorija - Company finances
|
EUR
|
2021
From: 2021-10-22
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 24,716 | 75,814 | 83,458 | 91,500 | 113,473 |
| Profit before tax | 18,166 | 3,875 | 26,941 | 31,444 | 22,666 |
| Net profit | 18,166 | 3,680 | 25,544 | 29,871 | 21,301 |
| Equity | 18,167 | 21,847 | 26,296 | 56,167 | 28,331 |
| Liabilities | - | 1,351 | 1,689 | 4,001 | 2,945 |
| Non-current assets | 0 | 6,430 | 8,801 | 6,271 | 3,470 |
| Current assets | 18,668 | 16,768 | 19,184 | 53,897 | 27,806 |
| Total assets | 18,668 | 23,198 | 27,985 | 60,168 | 31,276 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 2,448 | 11,023 | 11,454 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | +206.7% | +10.1% | +9.6% | +24.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 97.3% | 15.9% | 91.3% | 49.6% | 68.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | 16.8% | 97.1% | 53.2% | 75.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 73.5% | 4.9% | 30.6% | 32.6% | 18.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 73.5% | 5.1% | 32.3% | 34.4% | 20.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 0.1 | 0.1 | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
GP laboratorija - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-11-03 | 2023-11-30 | 13.82 |
| 2023-09-01 | 2023-09-30 | 13.82 |
| 2023-04-03 | 2023-04-30 | 13.82 |
| 2023-02-01 | 2023-03-31 | 13.82 |
| 2022-11-03 | 2022-12-31 | 6.14 |
| 2022-10-03 | 2022-10-31 | 6.14 |
| 2022-08-02 | 2022-09-30 | 6.14 |
| 2022-05-03 | 2022-07-31 | 6.14 |
| 2022-03-01 | 2022-04-30 | 6.14 |
GP laboratorija - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company GP laboratorija is: 1 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-02 | 2026-09-02 | 1.08 |
| 2026-08-31 | 2026-09-01 | 208.62 |
| 2026-08-14 | 2026-08-30 | 208.65 |
| 2026-06-19 | 2026-08-13 | 1.11 |
| 2026-03-20 | 2026-04-20 | 13.0 |
| 2026-03-08 | 2026-03-08 | 13.0 |
| 2026-02-18 | 2026-02-18 | 461.2 |
| 2025-02-18 | 2025-02-18 | 2781.47 |
| 2024-06-30 | 2025-02-15 | 0.48 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
GP laboratorija, MB (code 305921285) is a Small partnership engaged in the manufacture of other medical and dental devices, instruments and supplies. In 2025, the company generated revenue of €113.5K, up 24.0% year on year and 36.0% over two years. Net profit was €21.3K, compared with €29.9K in 2024 and €25.5K in 2023, while the net profit margin decreased to 18.8% from 32.6% in 2024 and 30.6% in 2023. The latest year therefore shows continued sales growth but lower profitability than in the previous two years. Balance sheet size also changed materially: total assets were €31.3K in 2025, down from €60.2K in 2024, with equity at €28.3K and liabilities at €2.9K. The equity ratio remained high at 90.6%, and debt to equity was 0.10, indicating a low leverage position. Asset turnover was 3.63x, while ROE reached 75.2% and ROA 68.1%, reflecting strong returns on a relatively compact asset base.